September 17, 2020: The Centre for Probe Development and Commercialization (CPDC) and adMare BioInnovations (adMare) are pleased to announce they have formed a new collaboration, “The CPDC-adMare Radiopharmaceutical Initiative (CARI)” to bring their respective resources together to advance an area of tremendous therapeutic and commercial potential in which Canada can gain a considerable global competitive advantage: radiopharmaceuticals. This field revolutionized precision medicine by the use of theranostics where targeted therapies are combined with diagnosis, treatment planning, drug delivery, and response assessment to improve cancer patient outcomes.
The objectives of CARI are for CPDC and adMare to seek out and uncover radiopharmaceutical opportunities arising from academic discoveries and early enterprises, establish rigorous drug development programs around selected opportunities, and drive the generation of proof-of-principle as well as other data supportive of the commercialization of new radiopharmaceutical assets.
Dr. Lana Janes, adMare Venture Partner commented, “Radiopharmaceuticals have shown tremendous promise for the treatment of cancers with significant unmet medical need; and with the strengths Canada holds in this area, we have an opportunity to be a world leader in bringing these novel therapeutics to patients. We look forward to working with both academic researchers and Canadian biotech companies to make this a reality.”
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
“It’s a very exciting prospect to be able to support emerging radiopharmaceutical opportunities across Canada. Leveraging existing platforms to support new radiopharmaceutical assets strengthens Canada’s position as a global leader in radioisotope based health care technologies” stated Justyna Kelly, CPDC’s Chief Executive Officer. “We look forward to working with adMare to enhance and accelerate emerging radiopharmaceuticals.”
adMare and CDPC are both leading and critical organizations in the commercialization of Canadian health research, each with substantial world-class expertise to be brought to bear on this emerging area that can make a tremendous impact on the health of patients and the Canadian bioeconomy. By doing so, through CARI they are offering:
Academic researchers a pathway to advance their cutting-edge research;
Canadian biotech companies the resources they need to advance their pipelines and build corporate value;